AssetMark Inc’s CRISPR Therapeutics CRSP Stock Holding History

AssetMark Inc’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.31K	Buy	134 +90	+205%	+$4.74K	﹤0.01%	2566
2026 Q1	$2.09K	Sell	44 -4	-8%	-$211	﹤0.01%	2839
2025 Q4	$2.52K	Sell	48 -1	-2%	-$60	﹤0.01%	2706
2025 Q3	$3.18K	Buy	49 +6	+14%	+$344	﹤0.01%	2490
2025 Q2	$2.09K	Buy	43 +32	+291%	+$1.24K	﹤0.01%	2417
2025 Q1	$374	Sell	11 -4	-27%	-$170	﹤0.01%	2462
2024 Q4	$590	Buy	+15	New	+$708	﹤0.01%	2347
2024 Q3	–	Sell	-4	Closed	-$216	–	2278
2024 Q2	$216	Sell	4 -7	-64%	-$405	﹤0.01%	2001
2024 Q1	$750	Buy	+11	New	+$787	﹤0.01%	1695
2022 Q2	–	Sell	-55	Closed	-$3K	–	1504
2022 Q1	$3K	Buy	+55	New	+$3.45K	﹤0.01%	1350

Other funds holding CRSP

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

CCIA

Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

AssetMark Inc's CRSP Position: Q2 2026 in Review

AssetMark Inc increased its CRISPR Therapeutics (CRSP) stake by 205% in Q2 2026, buying an estimated $4.74K and bringing the position to 134 shares worth $7.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2566.

AssetMark Inc first reported a position in CRSP in Q1 2022 and has held it in 10 quarters since. 195 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

AssetMark Inc held 134 shares of CRISPR Therapeutics worth $7.31K as of Q2 2026.
AssetMark Inc bought 90 CRISPR Therapeutics shares in Q2 2026, an estimated $4.74K.
CRISPR Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2566 holding.
AssetMark Inc first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 10 quarters since.
195 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.